What Is the Difference Between APOE2, APOE3, and APOE4?

A plain-language breakdown of APOE2, APOE3 and APOE4 — risk by copy number, ancestry limits, cholesterol effects, and when genotype changes treatment.

APOE2, APOE3, and APOE4 are three common versions of the same gene, and the difference between them is how much they raise or lower your risk of late-onset Alzheimer's disease. APOE4 raises it, APOE2 lowers it, and APOE3 — the most common version — is the neutral middle against which the other two are measured.

APOE codes for apolipoprotein E, a protein that carries cholesterol and other fats around the body and the brain. Everyone has two copies of the gene, one from each parent, so your genotype is a pair: e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, or e4/e4. According to MedlinePlus Genetics at the NIH, e3 is the most common allele in the general population, which is why most people carry at least one copy of it.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What each version actually does to risk

The three alleles differ by tiny changes in the protein's structure, but the downstream effects are large. An NIA-funded review describes e4 as the strongest common genetic risk factor for late-onset Alzheimer's and e2 as the strongest common protective one, with e3 treated as the risk-neutral baseline. APOE4 does two things at once: it raises the chance of developing the disease and it lowers the age at which symptoms start. Risk also scales with how many copies you carry.

Summarizing the largest APOE datasets, Alzforum puts the increase at roughly three to four times with one e4 copy and about ten to fifteen times with two, compared with the e3/e3 baseline. Protection works the same way in reverse. In neuropathologically confirmed cases analyzed in Nature Communications, the e2/e2 genotype carried an odds ratio of 0.004 against the highest-risk e4/e4 genotype, and e2 carriers had an older average age at symptom onset. That is a very large difference, but it is a shift in odds, not immunity — e2 carriers do develop Alzheimer's.

Why two copies of e4 is treated differently

Carrying two copies of e4 is no longer described as the far end of a risk scale. In a 2024 Nature Medicine study, Fortea and colleagues pooled more than 13,000 participants — 273 e4 homozygote brain donors from NACC plus 519 homozygotes across five biomarker cohorts — and found that nearly all e4/e4 carriers had Alzheimer's pathology in the brain. The timing was striking.

Biomarkers in e4/e4 carriers began diverging from e3/e3 carriers from age 55, and 88% were biomarker-positive by age 80. Symptom onset was both earlier and more consistent. As the NIA reported, onset in e4/e4 carriers averaged 65.1 years with a narrower prediction interval than in e3/e3 carriers — predictable enough that the authors argue e4 homozygosity should be considered a distinct genetic form of Alzheimer's rather than simply a risk category.

The numbers do not apply equally to everyone

The familiar 3–4x and 10–15x figures come mostly from White and European-ancestry cohorts, and they do not transfer cleanly. A 2025 review in Human Genetics reports that e4 odds ratios are consistently smaller in Hispanic and Black populations than in White and East Asian ones. Allele frequency differs too, and in a direction that complicates assumptions.

The same review gives e4 frequencies of roughly 9% in Asian populations, 12% in Hispanic, 14% in White, and 19% in African — so the group with the highest e4 frequency is not the group where e4 carries the largest measured effect. The practical consequence: if you have been given a risk multiple after a genetic test, ask which population it was derived from. A number quoted without that context may overstate or understate what the genotype means for you.

APOE is also a cholesterol gene

The three isoforms handle fats differently, and this is the part most Alzheimer's coverage skips. Work published in the Journal of Clinical Investigation found that apoE2 — the R158C variant — binds the LDL receptor at under about 2% of apoE3's affinity, which impairs clearance of chylomicron and VLDL remnants from the blood. That makes e2/e2 the main genotype behind type III hyperlipoproteinemia, a lipid disorder marked by elevated remnant particles.

The association is strong but far from deterministic: only about 10–15% of e2 homozygotes actually develop the phenotype, so the genotype is a predisposition that usually needs a second trigger. The point for readers is that APOE results carry information outside the brain. A protective brain genotype can coincide with a lipid risk worth discussing with a physician.

When genotype changes a treatment decision

APOE status now has a direct clinical use. The FDA prescribing information for Leqembi (lecanemab) states that ApoE e4 homozygotes have a higher incidence of ARIA — amyloid-related imaging abnormalities, meaning brain swelling or small bleeds visible on MRI — including symptomatic and serious ARIA, than heterozygotes or noncarriers. The label directs that testing be done before starting treatment, after discussing the implications with the patient.

The US position is that homozygotes may still be treated; the testing requirement exists so the higher risk is known and discussed first. Other regulators drew the line elsewhere. Australia's TGA-approved product information, dated 24 September 2025, states that Leqembi is not indicated in ApoE e4 homozygous patients at all. Same drug, same genotype, two different answers — so where you are treated affects what your genotype means for eligibility.

What to do with a result you already have

APOE testing is not a diagnosis and does not tell you whether you will develop dementia. It is probability information, and it is most useful when tied to a specific decision.

If you are considering testing rather than interpreting a result, decide in advance what you would do differently with each possible answer. For an e3/e3 result the answer is often nothing, and for an e4/e4 result the biomarker divergence from age 55 reported in the Nature Medicine analysis means the information may arrive decades before any symptom.

  • Write down your full genotype, not just whether you are "APOE4 positive." One copy and two copies are materially different.
  • Ask which population your reported risk estimate came from, given the ancestry differences above.
  • Bring the result to any conversation about anti-amyloid treatment, since homozygote status changes the ARIA discussion and, in some countries, eligibility.
  • Mention it to whoever manages your cholesterol, particularly with an e2/e2 result.
  • Share it with family only after deciding you want to — your genotype implies information about your parents, siblings, and children.

Frequently Asked Questions

Does having APOE4 mean I will definitely get Alzheimer's?

No. One copy raises risk roughly three to four times over the e3/e3 baseline, which is an increase in probability, not a certainty. Two copies are different in kind: the 2024 Nature Medicine analysis found nearly all e4/e4 brain donors had Alzheimer's pathology, which is why the authors treat homozygosity as a genetic form of the disease.

Can my APOE genotype change?

No. You inherit one allele from each parent and the pair is fixed for life. What changes is how much is known about what that pair predicts.

Is APOE2 always good news?

Not entirely. It is strongly protective against Alzheimer's, but apoE2 clears fat remnants from the blood poorly, and e2/e2 is the main genotype behind type III hyperlipoproteinemia.

Which genotype is most common?

e3/e3, because e3 is the most common allele in the general population per MedlinePlus Genetics. It is the baseline the other genotypes are compared against.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.